Brian Abrahams | Source | Managing Director and Co-Head of Biotechnology Equity Research at RBC Capital...
Brian Abrahams
Dr. Brian Abrahams joined RBC Capital Markets in July 2017 as a senior analyst covering the biotechnology sector. He has 15 years of experience following large, mid, and small cap biotech companies, and prior to RBC spent time in biotechnology equity research at Jefferies, Wells Fargo, and CIBC World Markets / Oppenheimer & Co. He is a licensed non-practicing physician and holds a medical degree from the Albert Einstein College of Medicine. He did his undergraduate studies at Yale University, where he graduated magna cum laude with a Bachelor of Science degree in Molecular Biophysics & Biochemistry.
-
RBC Capital Markets
Managing Director and Co-Head of Biotechnology Equity Research
-
The FDA Is About to Make Some Major Drug Decisions. What Investors Need to Know.
The agency has plenty on its plate in the coming months.
Article -
Latest COVID-19 wave likely to cause another 115,000 U.S. deaths by year-end, analysts say
Deaths could climb even more if hospital ERs and intensive care units are swamped, according to a Wall Street firm.
Article -
The descent of van de Stolpe: Galapagos CEO exits after R&D setbacks wipe out billions in value
Exits are hard to time. Onno van de Stolpe rode high for years after founding Galapagos. Yet, after presiding over a period in which Galapagos’ share price fell 80%, wiping out billions of dollars in value, van de Stolpe is hitting the exit on a low ebb—and leaving with the future of the biotech in doubt.
Article
-
We're now dealing with a much more transmissible variant that might also break through some degree of immunity protection. By the time we roll into 2022, a large enough amount of the U.S. population will have been either vaccinated or exposed to COVID such that the high transmission rates will slow.
-
Though van de Stolpe was well-liked for his humility, integrity, and transparency, given the company's recent high-profile setbacks, we expect investors will view the potential for new leadership as an opportunity to bring in fresh perspectives as the company looks to rework their internal R&D processes.